Vaxine’s aim as a leading biotechnology company at the cutting edge of vaccine science, is to prove that a pharma company don’t need to be big in order to have global impact.
Vaxine believes that the quality of the underlying science and an ability to efficiently translate that science to human products is what is critical to having global impact, rather than company size.
This explains how despite its compact size Vaxine continues to make multiple world first’s beating the world’s largest and best resourced pharma companies in doing so.
These include the first swine flu pandemic vaccine in the world in 2009, the first AI-designed vaccine in the world in 2019, and the first approved recombinant spike protein vaccine in 2021.
At the same time as managing these successful product launches, Vaxine remains true to its core scientific mission to advance knowledge and support cutting-edge research and continues to successfully publish 15-20 scientific research papers every year.